Breast cancer is one of the most personal and serious health issues facing women in the Western world. Israeli women share this threat and concern.
One in every nine woman in Israel will develop the disease sometime in her lifetime. More than 3000 women are diagnosed annually in this country, and some 700 women die from breast cancer every year. Early detection programs may be responsible for more early stage detection of the disease, and for the fact that more young women are confronted with this life-threatening situation.
The understanding of the genetics of the disease may also play a role in the epidemiological aspects of breast cancer. The diversity of the cultural backgrounds of women in Israel shows that the disease is more prominent among women with a western origin than among those with an eastern background. However, the most serious increase in the incidence of breast cancer has been seen in Israeli born women and in the non-Jewish, mainly the Arab, population.
Changes in the attitude towards breast cancer treatment throughout North America and Europe are now integrating into the Israeli health care system. Women talk more openly and freely about their disease, and political advocacy and activism are more common and influence treatment and care. Breast cacancer treatment in Israel is more tailored to the needs of the individual woman, and a multidisciplinary comprehensive approach is what women ask and expect from their health providers.
At the end of the 2nd European Breast Cancer Conference, held in Brussels in September 2000, a statement was established. This statement claimed that: “The conference demands that national governments establish and accredit breast units in their countries…” The same statement stressed the importance of a multidisciplinary team to be at the core of such units. The Israeli Breast Cancer Coalition decided to advocate and work towards the establishment of such centers. Some efforts have been already implemented into practice in this country. In this paper, a description is given to the proposed Breast Care Center to be established at the Hadassah Medical Organization.
A General Description of the
Hadassah Breast Cancer Treatment Center in Israel
The Hadassah Breast cancer treatment Center is to be established with the aim of providing multidisciplinary comprehensive care for women with breast cancer. In a specially dedicated medical setting, women will be offered diagnostic procedures, a plan for cancer treatment in Israerl, as well as follow-up services for their various breast conditions. The cancer treatment center integrates the expertise of radiation and medical oncologists, breast surgeons, and specialists in radiology, pathology, social work, nursing and psychology. The priorities of the center will be based on the provision of state of the art care, patient-centered care, clinical research, education and community outreach.
Highlighting of Unique Aspects of the Breast Care Center.
ý Single access Point
The Hadassah Breast Care Center will offer women a single point of access into the health system. A dedicated telephone line will be available staffed by a trained personal who has the skill to triage women to the appropriate next step and handle their records and referral needs. This member of staff will also have the ability to assure women that they will be taken care of and followed within the medical system.
ý Clinical Nurse Specialist
The day-to-day coordination of the Breast Care Center will be managed by a trained and dedicated Breast Care Clinical Nurse Specialist. Her role is to follow women with breast problems from the access point of entry and help them navigate within the system by coordinating all aspects of their treatment and care. She will continue to be their main contact address across their entire continuum of management and follow-up. Moreover, the Clinical Nurse Specialist will provide women with information and help them to make decisions regarding their care. She will also provide emotional and psychological support and refer women to other sources of support when needed.
ý Multidisciplinary Breast cancer treatment Program
The Hadassah Breast Care Center will offer women who have been diagnosed with breast cancer a Multidisciplinary Breast Care Program. In a single outpatient visit, women will meet individually with the physicians and nurses in their provider team, which is comprised of a breast surgeon, medical oncologist and a nurse specialist. During the session, the provider team will meet to discuss each patient’s case and develop a recommended treatment plan. A breast imaging specialist and pathologist will be also in attendance to consult on mammograms and pathology slides. Social work and psychological medicine are also to be available. The benefit for women is that, in one convenient session, they will meet all of their breast health providers, have their case reviewed by a team of specialists, and receive an individualized and tailored plan of care.
ý Cancer Risk Evaluation Program
The Cancer Risk Evaluation Program will be developed for women who are concerned about having an increased risk of breast and/or ovarian cancer. Women will be given the opportunity to meet with a medical oncologist and genetic counselor who have an expertise in risk assessment. The goal of this effort is to address the concerns of a woman who, for reasons of strong family history, may wish to discuss her particular degree of risk, appropriate management of that risk, and the issue of genetic counseling and screening.
ý The Psycho-oncology Services
The Psycho-oncology services will offer women a program designed to assist with managing psychological stress and anxiety related to the diagnosis and treatment, and help in increasing coping skills and modifying adverse life-style behaviors. The program will include individualized psychological care as well as ongoing group sessions to women according to ages and stages of disease. Patients will learn to take an active role in their own care through a variety of relaxation techniques, which help reduce anxiety and fear such as from the side-effects of chemotherapy, and help to enhance feelings of control and hope.
ý Information and Learning Center
The Breast cancer treatment Center patients will be referred to the Information Center to learn more about their health and their particular breast cancer treatment in Israel. The Information Center is free and is located near the Center. Patients, health visitors and all members of the community can access an extensive collection of books, periodicals, videos, and computer software and internet on wide variety of women’s health issues in general, and breast problems in particular. Visiting the Information Center may help women and their families to formulate questions when they meet the multidisciplinary team. In addition, the Center will empower women who have breast cancer so that they can make informed choices in relation to their treatment and care.
ý Patient to Patient – the Reach for Recovery Program
The Reach for Recovery Program will provide a free support program for women with breast cancer. Staffed by volunteers, who have all experienced breast cancer and its treatment, this program offers additional avenue of support and insight.
ý Patient Satisfaction
The Breast cancer treatment Center will be committed to continually improve its program and facilities. Patient satisfaction will be monitored annually by a special survey developed for this purpose. Action steps to address will be taken.
ý Research and Education
The world's Breast cancer treatment Center in Israel will serve as a venue for clinical, as well as psychosocial research. Issues related to environmental factors and breast cancer, the genetic aspect of the disease and epidemiological factors will be of main interest for such ongoing research. The center will also join other academic and established medical institutions in conducting clinical and basic research. Psychosocial research will also be done and evaluated in practice. Educational activities of medical and non-medical staff will be carried out at the center.
Here are the search results from the
National Center for Biotechnology Information (NCBI)
at the U.S. National Library of Medicine (NLM)
Items 1 -18 of 18
|
1: |
Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T, Lotem M.
|
Related Articles, Gene, Gene (GeneRIF), HomoloGene, Nucleotide (RefSeq), Nucleotide (Weighted), Protein (RefSeq), Protein (Weighted), Taxonomy via GenBank, UniGene, GEO Profiles, LinkOut
|
|
|
Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin. Fam Cancer. 2008 Aug 5. [Epub ahead of print] PMID: 18679827 [PubMed - as supplied by publisher] |
|
2: |
Kadouri L, Kote-Jarai Z, Hubert A, Baras M, Abeliovich D, Hamburger T, Peretz T, Eeles RA.
|
Related Articles, Gene, Gene (GeneRIF), HomoloGene, Nucleotide (RefSeq), Nucleotide (Weighted), Protein (RefSeq), Protein (Weighted), Substance (MeSH Keyword), Taxonomy via GenBank, UniGene, GEO Profiles, LinkOut
|
|
|
Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. Br J Cancer. 2008 Jun 17;98(12):2006-10. Epub 2008 May 27. PMID: 18542066 [PubMed - indexed for MEDLINE] |
|
3: |
Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, Abeliovich D, Peretz T.
|
Related Articles, Gene, Gene (GeneRIF), Gene (OMIM), HomoloGene, Nucleotide (RefSeq), Nucleotide (Weighted), OMIM (calculated), OMIM (cited), Protein (RefSeq), Protein (Weighted), Taxonomy via GenBank, UniGene, GEO Profiles, LinkOut
|
|
|
Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet. 2007 Jul;44(7):467-71. Epub 2007 Feb 16. PMID: 17307836 [PubMed - indexed for MEDLINE] |
|
4: |
Kadouri L, Bercovich D, Elimelech A, Lerer I, Sagi M, Glusman G, Shochat C, Korem S, Hamburger T, Nissan A, Abu-Halaf N, Badrriyah M, Abeliovich D, Peretz T.
|
Related Articles, Cited Articles, Gene, Gene (GeneRIF), HomoloGene, Nucleotide (RefSeq), Nucleotide (Weighted), Protein (RefSeq), Protein (Weighted), Taxonomy via GenBank, UniGene, GEO Profiles, Free in PMC, Cited in PMC, LinkOut
|
|
|
A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer. BMC Cancer. 2007 Jan 18;7:14. PMID: 17233897 [PubMed - indexed for MEDLINE] |
|
5: |
Kram V, Peretz T, Sagi M.
|
Related Articles, LinkOut
|
|
|
Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing. Fam Cancer. 2006;5(4):327-35. Epub 2006 May 25. Erratum in: Fam Cancer. 2007;6(1):159. PMID: 16724248 [PubMed - indexed for MEDLINE] |
|
6: |
Daum H, Sagi M, Pikarsky E, Pruss D, Hamburger T, Peretz T.
|
Related Articles, Gene, Gene (GeneRIF), HomoloGene, Nucleotide (RefSeq), Nucleotide (Weighted), Protein (RefSeq), Protein (Weighted), Taxonomy via GenBank, UniGene, GEO Profiles, LinkOut
|
|
|
[Prophylactic oophorectomy among carriers of BRCA1/2 mutations--demographic and pathologic data] Harefuah. 2006 Jan;145(1):13-7, 79-80. Hebrew. PMID: 16450717 [PubMed - indexed for MEDLINE] |
|
10: |
Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, Glaser B, Hamburger T, Eeles RA, Peretz T.
|
Related Articles, Gene, Gene (GeneRIF), HomoloGene, Nucleotide (RefSeq), Nucleotide (Weighted), OMIM (calculated), Protein (RefSeq), Protein (Weighted), Taxonomy via GenBank, UniGene, GEO Profiles, Cited in PMC, LinkOut
|
|
|
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer. 2004 May 17;90(10):2002-5. PMID: 15138485 [PubMed - indexed for MEDLINE] |
|
11: |
Kadouri L, Kote-Jarai Z, Easton DF, Hubert A, Hamoudi R, Glaser B, Abeliovich D, Peretz T, Eeles RA.
|
Related Articles, Compound (MeSH Keyword), Gene, Gene (GeneRIF), HomoloGene, Nucleotide (RefSeq), Nucleotide (Weighted), Protein (RefSeq), Protein (Weighted), Substance (MeSH Keyword), Taxonomy via GenBank, UniGene, GEO Profiles, Cited in PMC, LinkOut
|
|
|
Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. Int J Cancer. 2004 Jan 20;108(3):399-403. PMID: 14648706 [PubMed - indexed for MEDLINE] |
|
12: |
Elkin M, Cohen I, Zcharia E, Orgel A, Guatta-Rangini Z, Peretz T, Vlodavsky I, Kleinman HK.
|
Related Articles, Substance (MeSH Keyword), Cited in PMC, LinkOut
|
|
|
Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res. 2003 Dec 15;63(24):8821-6. PMID: 14695198 [PubMed - indexed for MEDLINE] |
|
13: |
Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R, Rizel S, Struewing JP, Modan B.
|
Related Articles, Gene, Gene (GeneRIF), HomoloGene, Nucleotide (RefSeq), Nucleotide (Weighted), Protein (RefSeq), Protein (Weighted), Taxonomy via GenBank, UniGene, GEO Profiles, LinkOut
|
|
|
Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. Gynecol Oncol. 2003 Jun;89(3):494-8. PMID: 12798717 [PubMed - indexed for MEDLINE] |
|
14: |
Thompson D, Szabo CI, Mangion J, Oldenburg RA, Odefrey F, Seal S, Barfoot R, Kroeze-Jansema K, Teare D, Rahman N, Renard H, Mann G, Hopper JL, Buys SS, Andrulis IL, Senie R, Daly MB, West D, Ostrander EA, Offit K, Peretz T, Osorio A, Benitez J, Nathanson KL, Sinilnikova OM, Olàh E, Bignon YJ, Ruiz P, Badzioch MD, Vasen HF, Futreal AP, Phelan CM, Narod SA, Lynch HT, Ponder BA, Eeles RA, Meijers-Heijboer H, Stoppa-Lyonnet D, Couch FJ, Eccles DM, Evans DG, Chang-Claude J, Lenoir G, Weber BL, Devilee P, Easton DF, Goldgar DE, Stratton MR; KConFab Consortium.
|
Related Articles, Cited Articles, Gene, Gene (GeneRIF), Gene (OMIM), OMIM (calculated), OMIM (cited), Taxonomy via GenBank, UniSTS, Free in PMC, Cited in PMC, LinkOut
|
|
|
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):827-31. Epub 2002 Jan 15. PMID: 11792833 [PubMed - indexed for MEDLINE] |
|
15: |
Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, Peretz T, Eeles RA.
|
Related Articles, Gene, Gene (GeneRIF), HomoloGene, Nucleotide (RefSeq), Nucleotide (Weighted), Protein (RefSeq), Protein (Weighted), Taxonomy via GenBank, UniGene, GEO Profiles, Cited in PMC, LinkOut
|
|
|
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer. 2001 Jul 6;85(1):36-40. PMID: 11437399 [PubMed - indexed for MEDLINE] |
|
16: |
Wang T, Lerer I, Gueta Z, Sagi M, Kadouri L, Peretz T, Abeliovich D.
|
Related Articles, Compound (MeSH Keyword), OMIM (calculated), Substance (MeSH Keyword), Cited in PMC, LinkOut
|
|
|
A deletion/insertion mutation in the BRCA2 gene in a breast cancer family: a possible role of the Alu-polyA tail in the evolution of the deletion. Genes Chromosomes Cancer. 2001 May;31(1):91-5. PMID: 11284040 [PubMed - indexed for MEDLINE] |
|
17: |
Manning AP, Abelovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, Robidoux A, Peretz T, Narod SA, Mes-Masson AM, Foulkes WD, Wang T, Morgan K, Fujiwara TM, Tonin PN.
|
Related Articles, OMIM (calculated), UniSTS, Cited in PMC, LinkOut
|
|
|
Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered. 2001;52(2):116-20. PMID: 11512557 [PubMed - indexed for MEDLINE] |
|
18: |
Hubert A, Peretz T, Manor O, Kaduri L, Wienberg N, Lerer I, Sagi M, Abeliovich D.
|
Related Articles, Gene (OMIM), Nucleotide (Weighted), OMIM (calculated), OMIM (cited), Protein (Weighted), Free in PMC, Cited in PMC, LinkOut
|
|
|
The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet. 1999 Sep;65(3):921-4. No abstract available. PMID: 10441598 [PubMed - indexed for MEDLINE] |
Here are links to full articles on Breast Cancer
Published in the last years
PMID: 18679827 PMID: 17307836
PMID: 17233897 PMID: 16724248
PMID: 16085232
|